However, the authors referred that increased lymphoma rates observed with anti-TNF therapy may reflect channeling bias, whereby patients with the highest risk of lymphoma preferentially receive anti-TNF therapy and consequently the data are insufficient to establish a causal relationship between RA treatments and the development of lymphoma [112]. The gene discussed is TNF; the disease is lymphoma.